GUO Xing,ZHAO Dan,ZUO Jinman.Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia[J].ZHONGGUO YAOFANG,2023,34(23):2910-2914.
GUO Xing,ZHAO Dan,ZUO Jinman.Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia[J].ZHONGGUO YAOFANG,2023,34(23):2910-2914. DOI: 10.6039/j.issn.1001-0408.2023.23.17.
Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia
To investigate the clinical efficacy and safety of herombopag combined with recombinant human thrombopoietin (rhTPO) in the treatment of primary immune thrombocytopenia (ITP) in the real world.
METHODS
2
A retrospective study was conducted on the patients diagnosed with ITP in the Second Affiliated Hospital of Bengbu Medical College from January 2021 to December 2022. Among them, 98 patients who were treated with a combination of herombopag and rhTPO were included in the observation group, and 157 patients who were treated with rhTPO alone were included in the control group. The changes in platelet count, clinical efficacy, bleeding, platelet transfusion rate and adverse drug reactions before and after treatment were observed and compared between the two groups.
RESULTS
2
Since the 8th day of treatment, there was a statistically significant difference in platelet count between the two groups [(61.04±13.46)×10
9
L
-1
in observation group, (52.11±12.06)×10
9
L
-1
in control group] (
P
<0.05), and there also was a statistically significant difference in the peak and stable values of platelet count between the two groups (
P
<0.05). The total effective rates of the observation group and the control group were 79.59% and 66.88%, with cumulative response rates of 81.32% and 68.68%, and median response durations of 8 days and 10 days, respectively; these differences were statistically significant (
P
<0.05). During the treatment period, the bleeding rates of the observation group and control group were 3.06% and 8.28% (
P
<0.05), bleeding events were categorized as grade 1 or 2, and platelet transfusion rates were 31.63% and 40.76%; the differences in bleeding rates and platelet transfusion rates between the two groups was statistically significant (
P
<0.05). The incidences of adverse drug reactions in the two groups were 11.22% and 9.55%, respectively, with no statistically significant difference (
P
>0.05), and no moderate to severe adverse drug reaction was found.
CONCLUSIONS
2
The combination of herombopag and rhTPO can significantly increase platelet levels and response rate, and reduce bleeding rate and platelet transfusion rate in ITP patients, with good safety.
关键词
海曲泊帕重组人血小板生成素原发免疫性血小板减少症疗效安全性
Keywords
recombinant human thrombopoietinprimary immune thrombocytopeniaclinical efficacysafety
KHELLAF M,VIALLARD J F,HAMIDOU M,et al. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia[J]. Haematologica,2013,98(6):881-887.
KIM Y K,LEE S S,JEONG S H,et al. Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia[J]. Blood Res,2015,50(1):19-25.
PARK R. Eltrombopag:a new treatment option for chronic refractory adult immune thrombocytopenia[J]. Blood Res,2015,50(1):1-2.
SYED Y Y. Hetrombopag:first approval[J]. Drugs,2021,81(13):1581-1585.
WANG Z L,CHEN L,ZHANG F K,et al. First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura[J]. J Thromb Haemost,2020,18(11):3053-3060.
ZHENG L,LIANG M Z,ZENG X L,et al. Safety,pharmacokinetics and pharmacodynamics of hetrombopag olamine,a novel TPO-R agonist,in healthy individuals[J]. Basic Clin Pharmacol Toxicol,2017,121(5):414-422.
XIE C Y,ZHAO H J,BAO X B,et al. Pharmacological characterization of hetrombopag,a novel orally active human thrombopoietin receptor agonist[J]. J Cell Mol Med,2018,22(11):5367-5377.
Thrombosis and Hemostasis Group,HematologyBranch,Chinese Medical Association. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia:version 2020[J]. Chin J Hematol,2020,41(8):617-623.
PUAVILAI T,THADANIPON K,RATTANASIRI S, et al. Treatment efficacy for adult persistent immune thrombocytopenia:a systematic review and network meta-analysis[J]. Br J Haematol,2020,188(3):450-459.
FOGARTY P F,TARANTINO M D,BRAINSKY A, et al. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia[J]. Curr Med Res Opin,2012,28(1):79-87.
LEE J Y,LEE J H,LEE H,et al. Epidemiology and ma- nagement of primary immune thrombocytopenia:a nationwide population-based study in Korea[J]. Thromb Res,2017,155:86-91.
MOULIS G,PALMARO A,MONTASTRUC J L,et al. Epidemiology of incident immune thrombocytopenia:a nationwide population-based study in France[J]. Blood,2014,124(22):3308-3315.
BASCIANO P A,BUSSEL J B. Thrombopoietin-receptor agonists[J]. Curr Opin Hematol,2012,19(5):392-398.
PENG G X,HE G S,CHANG H,et al. A multicenter phase Ⅱ study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy[J]. Ther Adv Hematol,2022,13:20406207221085197.
MEI H,LIU X F,LI Y,et al. A multicenter,randomized phase Ⅲ trial of hetrombopag:a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia[J]. J Hematol Oncol,2021,14(1):37.
WINER E S,SAFRAN H,KARASZEWSKA B,et al. Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy:a randomized,placebo-controlled phase 2 study[J]. Int J Hematol,2017,106(6):765-776.
Guidelines Working Committee of the Chinese Clinical Oncology Society. Chinese Clinical Oncology Association (CSCO) guidelines for the diagnosis and treatment of thrombocytopenia caused by tumor therapy:2023[M]. Beijing:People’s Health Publishing House,2023:20,38.
Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis
Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation
Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer: a meta-analysis
Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia
Reevaluation of systematic evaluation of Tripterygium glycosides in the treatment of diabetic kidney disease
Related Author
WANG Mingjie
XU Fengjin
ZHANG Yan
XUE Yan
WU Jiaqian
SU Dan
SHAO Tenghao
YU Zhanbiao
Related Institution
Dept. of General Medicine, Hengshui Municipal People’s Hospital
College of Clinical Medicine, Hebei Medical University
Dept. of Rheumatology and Immunology, Hengshui Municipal People’s Hospital
Dept. of Intensive Care Medicine, the Affiliated Hospital of Hebei University
Dept. of Intensive Care Medicine, the Fourth Hospital of Hebei Medical University